Keros Therapeutics, Inc. · Brief

Next report

4 days

Nov 4 · after closeest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

2 of 8≥ implied

Feb 26 '25±14.0%▲+0.64%×0.05

May 6 '25±9.5%▼−0.36%×0.04

Aug 6 '25±6.9%▼−7.29%×1.05

Oct 15 '25±30.0%▼−3.98%×0.13

Nov 5 '25±16.3%▲+3.32%×0.20

Q1 FY26±12.0%▼−14.96%×1.25

May 14 '26±32.2%▼−8.34%×0.26

Q2 FY26±25.5%▲+1.38%×0.05

quarterimplied−35%0+35%realized×

Q2 FY26±25.5%▲+1.38%×0.05

May '26±32.2%▼−8.34%×0.26

Q1 FY26±12.0%▼−14.96%×1.25

Nov '25±16.3%▲+3.32%×0.20

Oct '25±30.0%▼−3.98%×0.13

Aug '25±6.9%▼−7.29%×1.05

2 older reports

May '25±9.5%▼−0.36%×0.04

Feb '25±14.0%▲+0.64%×0.05

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 4 report · est.

Bull2 of 3

4disclosed supplier and customer ties in SEC filingsSEC filings

131managers reporting a position in the latest quarterly filings13F · Jun 30 '26

Bear2 of 4

6 of 8recent reports where the move came in under the options implied rangeEarnings history

0.01%of iShares Russell 2000 ETF's assets, the largest tracked-fund weightN-PORT · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

KROS report session

No linked exposure.

Oct 21impliedImplied move: ±34.0% into Nov 4 earnings (Oct 21 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.